Skip to main content

Table 5 Grade 3–4 Adverse events occurring in patients

From: Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

Adverse event

mFOLFIRINOX (n = 27)

N (%)

Gemox (n = 22)

N (%)

p value

Neutropenia

13 (48.1)

8 (36.4)

0.407

Febrile neutropenia

3 (11.1)

0

0.107

Anemia

1 (3.7)

2 (9.1)

0.434

Thrombocytopenia

0

1 (4.5)

0.263

Vomiting

7 (25.9)

1 (4.5)

0.044

Diarrhea

3 (11.1)

0

0.107

Peripheral neuropathy

2 (7.4)

3 (13.6)

0.474

Fatigue

1 (3.7)

0

0.362

  1. Bold values are statistically significant (p ≤ 0.05)